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Fetal oocytes in mammals undergo extensive apoptosis during development. In this issue of Developmental
Cell, Malki et al. (2014) provide insight into how and why such massive oocyte loss occurs through the
demonstration that the expression level of LINE-1 retrotransposon defines the survival threshold and thus
viability of fetal oocytes.During oocyte development, only a limited
fraction of the initial pool of fetal oocytes
survives through to postnatal follicular
growth and ovulation; most of the devel-
oping oocytes are lost via programmed
cell death during differentiation andmatu-
ration. While such developmental cell
death is widely observed in various so-
matic cell lineages (for example, in the
nervous system and the limb bud), germ
cell death is unique in that any selection
occurring among the cell population may
affect the genome and epigenome of the
next generation. Programmed cell death
of oocytes is first evident in female em-
bryos just after primordial germ cells enter
meiotic prophase I to become oocytes.
Starting from early meiosis, fetal oocyte
number dramatically decreases to one-
third to one-fourth of the original pool by
the time of birth (Tilly, 2001; Pepling,
2006). Previous genetic studies have
shown that such massive elimination of
early meiotic oocytes, often termed fetal
oocyte attrition, occurs via apoptotic
pathways. However, the primary trigger
of fetal oocyte attrition is unknown.
Whether extrinsic stimuli (such as growth
factor deprivation or niche competition)
transmit the death signal or whether
intrinsic mechanisms (such as cellular
responses to DNA damage or other
stresses) activate checkpoint-induced
apoptosis have also long been a matter
of debate.
One distinctive feature of fetal oocytes
is sustained genome-wide DNA hypome-
thylation. During germline development,
genomeCpGmethylationmarks are glob-
ally erased during primordial germ cell for-
mation. De novo DNA methylation is then
reestablished in fetal prospermatogonia
in the male, whereas in the female, globalhypomethylation is maintained in fetal
oocytes, with de novo DNA methylation
being imposed after birth (Schaefer
et al., 2007). The global erasure of
genome DNA methylation in the germline
is considered essential to reprogramming
epigenetic information toward gameto-
genesis and embryogenesis, but this
methylation loss also poses a potential
threat to the germline genome by reani-
mating mobile transposable elements.
Indeed, both prospermatogonia and fetal
oocytes express detectable levels of
transposons, although the developmental
consequences are unknown.
In this issue of Developmental Cell,
Malki et al. (2014) now connect LINE-1
retrotransposon activity to fetal oocyte
attrition in mice. LINE-1 is the most
abundant class of retrotransposons,
comprising about 20% of the mammalian
genome, with approximately 10,000
copies being full length in mice (Goodier
and Kazazian, 2008). The authors first
examined Maelstrom null fetal ovaries
to investigate a possible correlation be-
tween increased LINE-1 expression and
oocyte survival, as well as meiotic pro-
gression. Maelstrom, an evolutionarily
conserved HMG domain-containing pro-
tein preferentially expressed in the germ-
line, is essential for spermatogenesis
in mice and suppresses retrotransposons
through the regulation of germline-spe-
cific piwi-interacting small RNA (piRNA)
biogenesis (Soper et al., 2008). The piRNA
system primarily functions in the male
germline in mice, and its role in fe-
male reproduction remains unclear. One
recent study reported that retrotranspo-
son expression is increased in fetal oo-
cytes of several piRNA pathway mutants
but that the mutant females are fertileDevelopmental Cewith no apparent oogenesis defects (Lim
et al., 2013).
In the current study, Malki et al. (2014)
found that Maelstrom null ovaries show
increased fetal oocyte attrition and dimin-
ished oocyte reserve. The mutant females
have a shortened reproductive lifespan,
made evident by backcrossingMaelstrom
null mice to an inbred genetic back-
ground. LINE-1 retrotransposon expres-
sion was significantly upregulated in
Maelstrom null fetal oocytes (2- to 3-fold
increase, on average, relative to con-
trols), while expression of IAPs, another
major class of retrotransposons, was
not detectable in either Maelstrom null
or wild-type oocytes. The authors then
quantified in detail LINE-1 ORF1 protein,
one of the two proteins encoded by
LINE-1 (the other ORF2 protein is much
less abundant and very difficult to detect)
by immunofluorescence in developing
oocytes at embryonic day 15 (E15), E18,
and postnatal day 2 (P2). The surprise
from this immunohistological analysis is
that each oocyte expresses a highly vari-
able amount of LINE-1 ORF1. It appeared
that LINE-1 ORF1 levels in early fetal
oocytes (at E15) set the threshold for the
survival of later-stage oocytes (at E18
and P2). That is, assuming that early fetal
oocytes that experience excessive LINE-
1 expression above a certain threshold
are destined for apoptotic elimination,
then the survivor number from LINE-1
selection nicely matched what would
be predicted as the number of viable
oocytes at later stages. Consistent with
the involvement of LINE-1, whose trans-
poson activity induces genome DNA
damage, Maelstrom null oocytes associ-
ated with excessive LINE-1 expression
exhibit enhanced DNA strand breaksll 29, June 9, 2014 ª2014 Elsevier Inc. 501
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mosomes during meiotic prophase I,
which can activate checkpoint pathways
and trigger cell death.
To further investigate a more direct
consequence of LINE-1 overexpression,
the authors employed an inducible trans-
genic mouse system of LINE-1 and again
observed a significant correlation be-
tween the elevated levels of LINE-1
expression and reduced survival rates of
fetal oocytes, together with increased
meiotic defects, including unrepaired
DNA damage and asynapsis. Because a
single LINE-1 transgene induces only a
moderate increase in total LINE-1 expres-
sion in the presence of more than 10,000
full-length endogenous LINE-1 copies in
the genome, the phenotypes observed
by this transgenic experiment were some-
what milder than those seen in Maelstrom
null mutants. However, this gain-of-func-
tion experiment of LINE-1 corroborated
the idea that excessive LINE-1 expression
directly enhances fetal oocyte attrition,
possibly by inducing meiotic defects.
Given these observations, can inhibi-
tion of LINE-1 activity alleviate fetal
oocyte attrition? Side stepping the
challenges of knocking out numerous
copies of LINE-1 in the genome or RNAi
knockdown of LINE-1, whose widespread
sequences in transcriptome would likely
induce off-target effects, Malki et al.
(2014) made use of the nucleoside analog
azidothymidine (AZT), which inhibits
reverse transcriptase activity and thus
retrotransposon integration. Administra-
tion of AZT to pregnant female mice
resulted in a transient but remarkable
block of fetal oocyte attrition in both
wild-type and Maelstrom null genetic502 Developmental Cell 29, June 9, 2014 ª20backgrounds. Almost all of AZT-treated
wild-type oocytes (more than 90%) sur-
vived between E15 and E18. The viability
of AZT-treated Maelstrom null early oo-
cytes also recovered 2- to 3-fold between
E15 and E18 relative to untreated
mutants. The numbers of later oocytes
(at P2) dropped to almost similar levels
in both AZT-treated and untreated wild-
type ovaries, whereas in Maelstrom null
ovaries, AZT treatment still significantly
alleviated severe oocyte attrition at P2.
This transient—but not stable—effect of
AZT is attributable to the endonuclease
activity of LINE-1 in the presence of
AZT, which can induce DNA strand
breaks as the initial step of target-
primed retrotransposition before reverse
transcription and integration. Indeed,
AZT-treated wild-type fetal oocytes with
increased survival rate exhibited elevated
DNA damage together with meiotic
asynapsis. A possible explanation for
this observation is that reverse transcrip-
tase-dependent intermediates of LINE-1
retrotransposition exert a detrimental ef-
fect on early oocyte survival and meiosis
quality, whereas DNA damage induced
by LINE-1 endonuclease activity triggers
oocyte loss at later stages. Together,
these results provide a proof of principle
that fetal oocyte attrition can be modu-
lated by controlling LINE-1 activity.
With the discoveries reported in this
study, many new questions arise. For
example, it is still unclear whether LINE-1
expression is intrinsically regulated as
the primary trigger of fetal oocyte attrition
or whether extrinsic factors (such as
cellular stresses or nutritional environ-
ment) activate LINE-1 expression as a
downstream cell death mediator of such14 Elsevier Inc.extracellular cues. With respect to the
latter notion, it is well established that ret-
rotransposon expression is upregulated in
response to various cellular stimuli, such
as heat shock, DNA damage, and certain
chemical treatments in somatic cells.
Whether a similar mechanism operates
to induce LINE-1 in fetal oocytes needs
future investigation. It would also beworth
examining whether retrotransposon-
induced developmental cell death oper-
ates in somatic cell lineages or whether
such a mechanism is specific to oocytes
or germline cells in which extensive
cellular suicide is worth the cost to protect
the genomic information of the next gen-
eration. From a practical point of view, if
oocyte attrition can be suppressed by
artificially shutting down retrotransposon
activity, then this may present a possible
tool for extending female reproductive
lifespan without sacrificing oocyte quality.REFERENCES
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